Crinetics Pharmaceuticals
CRNX
140 hedge funds and large institutions have $974M invested in Crinetics Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 33 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
70% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 33
10% more capital invested
Capital invested by funds: $884M → $974M (+$89.8M)
9% more funds holding
Funds holding: 128 → 140 (+12)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2.09% less ownership
Funds ownership: 102.14% → 100.05% (-2.1%)
93% less call options, than puts
Call options by funds: $32K | Put options by funds: $446K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.7M |
| 2 |
BlackRock
New York
|
+$12.8M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.47M |
| 4 |
Jennison Associates
New York
|
+$9.2M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$5.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$44M |
| 2 |
PA
Perceptive Advisors
New York
|
-$32.1M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$27.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.64M |
| 5 |
Walleye Capital
New York
|
-$2.39M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
151
TCI Wealth Advisors
Tucson,
Arizona
| – | -$3.08K | -192 | Closed |
|
152
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2.25K | -140 | Closed |
|
|
AF
153
Allworth Financial
Folsom,
California
| – | -$1.61K | -100 | Closed |
|
|
NA
154
NewEdge Advisors
New Orleans,
Louisiana
| – | -$964 | -60 | Closed |
|
CRNX Hedge Fund Activity: Q2 2023 in Review
140 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2023, worth a combined $974M — up 10% from $884M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CRNX positions and 15 closed out — a net gain of 12 holders — while 56 added to existing stakes and 33 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $27.7M. The largest seller was BVF Inc, exiting entirely with an estimated $44M sold.
- 140 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2023, up from 128 in Q1 2023.
- Funds reported $974M of Crinetics Pharmaceuticals stock for Q2 2023, up 10% quarter-over-quarter.
- 27 funds opened new Crinetics Pharmaceuticals positions in Q2 2023 and 15 closed out, a net change of +12 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2023 was T. Rowe Price Associates, an estimated $27.7M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2023 was BVF Inc, an estimated $44M sold.
Based on aggregated 13F filings for Q2 2023.